Key result
While lower-quality unblinded trials suggested benefit, the highest-quality blinded trial showed catheter-based renal denervation did not reduce systolic blood pressure.
Why the study?
Does catheter-based renal sympathetic denervation reduce blood pressure in patients with resistant hypertension?
Systematic Review (n=1,476)
Does catheter-based renal sympathetic denervation reduce blood pressure in patients with resistant hypertension?
Answers are grounded in this paper and cite their sources.
While unblinded studies suggested significant blood pressure reductions with renal denervation, the highest quality sham-controlled trial (SYMPLICITY HTN-3) failed to demonstrate any benefit, highlighting the impact of bias in unblinded device trials.
OBJECTIVE: The objective of this study is to evaluate the efficacy and safety of renal denervation in patients with resistant hypertension. METHODS: We searched MEDLINE and EMBASE for studies that evaluated the use of catheter-based renal sympathetic denervation compared to a control group and reported blood pressure results at follow-up. Data was extracted from relevant studies and pooled estimates for blood pressure were determined using the inverse variance method for meta-analysis with mean difference. RESULTS: We identified 12 studies (three randomised controlled trials (n=688), eight prospective observational studies (n=478) and one observational study with matched controls (n=310)). Data from SYMPLICITY HTN-3, the only high-quality blinded randomised control trial suggests that there is no significant difference in change in systolic (-2.30 95% CI -6.90 to 2.30 mm Hg) or diastolic (-1.96 95% CI -4.98 to 1.06 mm Hg) blood pressure at 6 months. The pooled data from two unblinded trials of lower quality showed significant reduction in change in systolic (-27.36 95% CI -37.08 to -24.61 mm Hg) and diastolic blood pressure (-9.62 95% CI -14.51 to -4.72 mm Hg). In terms of safety, SYMPLICITY HTN-3 found no significant differences between treatment and control group in terms of death, myocardial infarction, new onset renal disease, stroke and hypertensive emergencies. CONCLUSIONS: In conclusion, while poor quality unblinded studies provide evidence that renal denervation using catheter-based systems is effective in reducing systolic and diastolic blood pressure in resistant hypertension, the largest randomised controlled trial to date (SYMPLICITY HTN-3) failed to demonstrate any benefit.
No takes yet. Share an insight, caveat, or question.
Kwok et al. (2014) conducted a systematic review in resistant hypertension (n=1,476). catheter-based renal sympathetic denervation vs. control group was evaluated on change in systolic blood pressure at 6 months (SYMPLICITY HTN-3 trial) (MD -2.30 mm Hg, 95% CI -6.90 to 2.30). While lower-quality unblinded trials suggested benefit, the highest-quality blinded trial showed catheter-based renal denervation did not reduce systolic blood pressure.
Synapse has enriched 10 related papers. Consider them for comparative context: